News
Vifor Pharma comments on market speculations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Due to current market speculations, Vifor Pharma Group states the following:
Vifor Pharma Group systematically reviews options that
Vifor Pharma announces changes to the Executive Committee as CFO retires
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021
Einladung: Straumann Group Webcast - Umsatzzahlen 1. Quartal 2022
Einladung: Straumann Group Webcast - Umsatzzahlen 1. Quartal 2022
Invitation: Straumann Group 2022 first-quarter sales webcast
Invitation: Straumann Group 2022 first-quarter sales webcast
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
DGAP-News: BB Biotech AG concludes its share buyback program and launches a new buyback program
DGAP-News: BB Biotech AG concludes its share buyback program and launches a new buyback program
DGAP-News: BB Biotech AG schliesst aktuelles Aktienrückkaufprogramm ab und lanciert ein neues Aktienrückkaufprogramm
DGAP-News: BB Biotech AG schliesst aktuelles Aktienrückkaufprogramm ab und lanciert ein neues Aktienrückkaufprogramm
Evolva's AGM postponed to May 5, 2022 / agenda remains unchanged
Evolva's AGM postponed to May 5, 2022 / agenda remains unchanged
Straumann Group shareholders elect Nadia Tarolli Schmidt as a new Board member and approve all further proposals
Straumann Group shareholders elect Nadia Tarolli Schmidt as a new Board member and approve all further proposals
Straumann Group Aktionärinnen und Aktionäre wählen Nadia Tarolli Schmidt als neues Mitglied des Verwaltungsrates und genehmigen alle weiteren Anträge
Straumann Group Aktionärinnen und Aktionäre wählen Nadia Tarolli Schmidt als neues Mitglied des Verwaltungsrates und genehmigen alle weiteren Anträge
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
Straumann Group announces new Executive Management Board members to support growth strategy
Straumann Group announces new Executive Management Board members to support growth strategy
Straumann Group ernennt neue Geschäftsleitungsmitglieder, um Wachstumsstrategie weiter voranzutreiben
Straumann Group ernennt neue Geschäftsleitungsmitglieder, um Wachstumsstrategie weiter voranzutreiben
Relief Reports Full-Year 2021 Results and Provides Corporate Update
Relief Reports Full-Year 2021 Results and Provides Corporate Update
Sonova schliesst Aktienrückkauf 2021-22 ab und lanciert neues dreijähriges Rückkaufprogramm von bis zu CHF 1,5 Mrd.
Sonova schliesst Aktienrückkauf 2021-22 ab und lanciert neues
dreijähriges Rückkaufprogramm von bis zu CHF 1,5 Mrd.
Sonova concludes 2021-22 share buyback and will start a new three-year buyback program of up to CHF 1.5 billion
Sonova concludes 2021-22 share buyback and will start
a new three-year buyback program of up to CHF 1.5 billion
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
Evolva's Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items:
Evolva's Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items:
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
DGAP-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu, genehmigt die Dividende von CHF 3.85 pro Aktie und wählt zwei neue Verwaltungsräte
DGAP-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu, genehmigt die Dividende von CHF 3.85 pro Aktie und wählt zwei neue Verwaltungsräte
DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members